Blinatumomab as first salvage versus second or later salvage in adults with relapsed/refractory B‐cell precursor acute lymphoblastic leukemia: Results of a pooled analysis-Reference-Cited by-同舟云学术

Blinatumomab as first salvage versus second or later salvage in adults with relapsed/refractory B‐cell precursor acute lymphoblastic leukemia: Results of a pooled analysis

Published:2021-03-18 Issue:8 Volume:10 Page:2601-2610
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Topp Max S.¹^ORCID,Stein Anthony S.²,Gökbuget Nicola³,Horst Heinz‐August⁴,Boissel Nicolas⁵,Martinelli Giovanni⁶,Kantarjian Hagop⁷^ORCID,Brüggemann Monika⁸,Chen Yuqi⁹,Zugmaier Gerhard¹⁰

Affiliation:

1. Medizinische Klinik und Poliklinik II Universitätsklinikum Würzburg Würzburg Germany

2. Gehr Leukemia Center City of Hope Medical Center Duarte CA USA

3. Medizinische Klinik III (Hämatologie/Onkologie/Rheumatologie/Infektiologie Universitätsklinikum Frankfurt Germany

4. Klinik für Innere Medizin II Universitätsklinikum Schleswig‐Holstein Kiel Germany

5. Unité d'Hématologie Adolescents et Jeunes Adultes Hôpital Saint‐Louis Paris France

6. Scientific Directorate Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS Meldola (FC) Italy

7. Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA

8. Sektion für Hämatologische Spezialdiagnostik Klinik für Innere Medizin II Universitätsklinikum Schleswig‐Holstein Kiel Germany

9. Global Biostatistical Science Amgen Inc Thousand Oaks California USA

10. Global Development Amgen Research (Munich) GmbH Munich Germany

Funder

Amgen

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.3731

Reference22 articles.

1. International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia

2. Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody

3. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct

4. Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct

5. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. BLINATUMOMAB IN THE THERAPY OF ACUTE B-LYMPHOID LEUKEMIA;Mediterranean Journal of Hematology and Infectious Diseases;2024-08-31

2. Liposomal mitoxantrone-based multidrug chemotherapy as a bridge to allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute lymphoblastic leukemia (ALL) after immunotherapy failure: a case report;Frontiers in Medicine;2024-05-22

3. Impact of minimal residual disease response and of status of disease on survival after blinatumomab in B-cell acute lymphoblastic leukemia: results from a real-life study;Annals of Hematology;2024-04-13

4. Impact of minimal residual disease response and of status of disease on survival after Blinatumomab in B-Cell Acute Lymphoblastic Leukemia: results from a Real-Life Study. Running title: MRD-response and Disease Status correlate with survival after Blinatumomab in ALL-B patients;2024-03-05

5. Blinatumomab improves outcomes for pediatric patients with low-risk B-cell acute lymphoblastic leukemia in first marrow relapse;Translational Pediatrics;2024-03